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ducted. The study population included CB patients aged40 with2 years contin-
uous enrollment in the HIRD, 1 inpatient (INPT) admission/emergency
department (ED) visit or 2 outpatient visits with CB (ICD-9-CM 491.xx) during the
period from January 1, 2004 to May 31, 2011, and 2 pharmacy fills for COPD med-
ications (the first fill served as the index date). CB patients were followed for 1 year
to collect all-cause and COPD-related (ICD-9 codes: 491.xx, 492.xx, 496.xx) health
care resource utilization (HCRU) and costs. Generalized Linear Models (GLM) with
gamma distribution and log link function were utilized to identify HCRU cost
predictors. RESULTS: A total of 17,382 treated CB patients met inclusion/exclusion
criteria (50.6% female, mean age 66.711.4 years). During follow-up year, themean
number of COPD maintenance medication fills was 7.66.3; all-cause HCRU was:
39%had 1 INPT, 26.6% had 1 ED visits, and 98.4% had 1 office visits; andmean
total all-cause HCRU cost was $25,747 $51,105. COPD-related HCRU was: 32.6%
had  1 INPT, 12.9% had  1 ED visits, and 81.8% had 1 office visits; mean total
COPD-related HCRU cost was $12,609$36,801. GLM models showed that baseline
incidence of COPD exacerbations was a significant predictor of both all-cause
(0.0924, p0.0001) and COPD-related (0.1862, p0.0001) HCRU costs during
follow-up. Other significant predictors of follow-up COPD-related costs included
Deyo-Charlson Index (0.1370, p0.0001), female gender ( -0.1280, p0.0001),
and age (0.0084, p0.0001). CONCLUSIONS: HCRU and costs among CB patients
treated with COPDmaintenance medications were considerable during follow-up.
New medications and disease management interventions aiming to reduce HCRU
and costs among CB patients warrant exploration.
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OBJECTIVES: Inhaled corticosteroids (ICSs) and long-acting beta-agonists (LABAs)
have been recommended for patients with moderate to severe persistent asthma.
This study quantified medication possession ratios (MPRs) for those asthmatic
patients and assessed the association between severe asthma exacerbations (SAEs)
and degree ofmedication compliance.METHODS:The primary data sourcewas the
MarketScan Multistate Medicaid database from 2002 to 2007. A total of 299,917
patients (ages 0-64) with moderate or severe asthma were selected. Drug use was
tracked for ICSs, LABAs, ICS/LABA combination drugs, short-acting beta agonists
leukotriene modifiers, and oral and IV steroids. An ICS-and-LABA MPR was calcu-
lated as the sum of days’ supply for ICS and LABA drugs divided by the number of
follow-up days during the first year after the patient’s asthma index date. Logistic
regressions were used to assess the risk of SAEs associated with degree of medica-
tion compliance. RESULTS: There were 21,852 (7.3%) patients with severe persis-
tent and 278,065 (92.7%) patients with moderate persistent asthma. Within 12
months after asthma index date, averageMPRswere 0.23 (median 0.14) for ICSs and
LABAs and 0.66 (median 0.46) across all asthma medications. After controlling for
covariates like age, gender, race, and comorbidities, the odds ratios of an asthma-
related emergency department (ED) visit was 0.81 (0.79-0.84) for a higher ICS-and-
LABA MPR, but the odds ratio of asthma-related hospitalization or intubation was
1.56 (1.50-1.62). Other key risk factors (p0.0001) included being African American,
having an alcohol/substance abuse disorder, pregnancy, obesity, and upper respi-
ratory tract infection. CONCLUSIONS: A higher ICS-and-LABA MPR appears to be
associated with a lower risk of asthma-related ED visits, but higher risk of asthma-
related hospitalization or intubation. Certain patients with asthma, such as preg-
nant adolescents and African Americans, seem particularly vulnerable to SAEs.
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OBJECTIVES: Sub-optimal beliefs about chronicity of asthma may interfere with
adherence to therapy and result in poor asthma control. Objective of the studywas
to characterize the beliefs about the chronicity of asthma and determine its asso-
ciation with medication adherence and self-management in asthma patients.
METHODS: Adult patients (n166) with previously diagnosed persistent asthma
visiting emergency room (March 2009-December 2009) of a public chest hospital of
Delhi for asthma exacerbation completed interviewer- administered questionnaire
on socio-demographics, clinical history, disease beliefs, use of inhaled corticoste-
roids (ICS), and self-management of asthma after stabilization of their condition.
RESULTS: The cohort had 54% patients in the age group of 30-40 years, 64% fe-
males, 11% illiterate, and 65% patients earning less than INR 10,000/month. Overall
87% patients believed that they had asthma when they are having symptoms,
which is called as no symptoms, no asthma belief. No association was found be-
tween no symptoms, no asthma belief with gender, income, family history of
asthma and co-morbidity. Younger patients in the age group 18-29 years had four
to fivefold greater odds and patients with education above 10th grade had three to
fourfold greater odds of having the no symptoms, no asthma belief or the acute
episodic belief. Acute episodic belief was negatively associated with beliefs about
always having asthma, asthma being a serious condition, having lung inflamma-
tion, or the importance of using ICS, and was positively associated with expecting
to be cured (p0.05). All patients irrespective of their belief of acute or chronic
nature of asthmahad poor adherence to the treatment and other self-management
behaviors. CONCLUSIONS: Majority of the asthma patients believed asthma as
acute episodic disease and had sub-optimal information about asthma. These be-
liefs need to be addressed by providing asthma education leading to medication
adherence and asthma control.
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OBJECTIVES:Non-adherence to a prescribed therapeutic program is an issue in the
treatment of chronic diseases more so for asthma, in which the lack of symptoms
may be interpreted as remission and beliefs about inhaled corticosteroid (ICS)
could also result in non-adherence. The objective of the study was to analyse the
self-reported adherence to ICS therapy and beliefs about medicine. METHODS:
Adult patients previously diagnosed with asthma and who were prescribed ICS,
visiting emergency room of a tertiary care public chest hospital for asthma exac-
erbation were recruited (March 2008-December 2009). Patients completed self-re-
ported questionnaire containing 49 questions on 6 domains: socio-demographic,
clinical profile, causal belief, self-report on adherence, beliefs aboutmedicines and
medication adherence report scale (MARS) after stabilization. RESULTS: Of the 200
patients, 51.5% were between 30-40 years, 64% were female, mean duration of
asthma was 10.58.1 years and 51.5% were having severe asthma. Salient findings
on self-report adherence were, 49% reported that they took ICS even if asymptom-
atic; 91% reported that they forgot to take their ICS some or most of the times; 84%
reported that they avoided ICS some of the times. In response to individual item for
MARS, 15.5% claimed that they took ICS as prescribed. Significant positive correla-
tion was observed between treatment necessity and reported adherence (r0.445,
p 0.001). Patients whowere concerned for the potential effects and risk of depen-
dence had low adherence with significantly negative correlation. Younger age
group had a significant correlation with social inhibition and female gender corre-
lated significantly with fear of adverse effects and social inhibition as the cause for
avoiding ICS. CONCLUSIONS: The findings support the model of treatment adher-
ence, which incorporated beliefs about treatment as well as illness perceptions.
The necessary-concerns offer a potentially useful framework to help clinicians
elicits key treatment beliefs influencing adherence to ICS.
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OBJECTIVES: Asthma is a chronic inflammatory disorder of the airways and the
prevalence of asthma has been increasing since the early 1980 across all age, gen-
der and racial groups. Current asthma treatment guidelines suggest combination
therapy of inhaled corticosteroid(ICS) and long acting beta agonist(LABA) for man-
agement of moderate to severe asthma. The primary objective was to identify
effects of adherence to combination therapy of LABA and ICS(LABAICS) on emer-
gency department(ED) utilization in newly diagnosed asthma patients. The sec-
ondary objective was to identify and use instrumental variables(IVs) to control for
sample selection bias.METHODS: A de-identified patient claims nationwide com-
mercial database was used to identify 7171 patients who were newly diagnosed
with asthma. Patient adherence to LABAICS was measured using Medication
Possession Ratio(MPR) with two years follow-up. IVs including medication copay
and a binary indicator variable for mail prescription order were tested for over-
identification and endogeneity using Sargan test and Hausman specification test.
Differences in ED visit by MPR and adherence group(PoorMPR80%,
GoodMPR80%) were analyzed by Cox proportional hazards model with a linear
transformation. RESULTS: Patients with good adherence were significantly older
than poor adherent patients(52 years vs. 48 years, p0.05) and had significantly
higher proportion of mail prescription order as well as medication copay. Every 1%
increase in MPR was associated with a risk of approximately 4% of having an ED
visit(HR3.72, p0.001) and the risk association for bivariate variable MPR in-
creased from 79% to a two-fold while controlling for gender, age, and comorbidi-
ties(HR2.03, p0.001). Only one instrument of proportion of prescription mail
order was accepted as the valid instrument and the results demonstrated that
every 1% increase in MPR was significantly associated with 4.9% of risk in utilizing
ED while holding other covariates constant(p0.001). CONCLUSIONS:We found a
risk association between high adherence and ED utilization in newly diagnosed
asthma patients with LABAICS.
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OBJECTIVES:Asthma is a prevalent conditionworld-wide, but little is known of the
awareness and impact of the condition among Brazilian adults. The current study
assessed awareness of asthma and whether asthma is associated with decreased
health-related quality of life (HRQoL) among Brazilians aged 18 years and older.
METHODS: Data were taken from the 2011 Brazil National Health and Wellness
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Survey (n12,000), a cross-sectional self-report survey which included the SF-12
Health Survey Version 2 (SF-12v2) to assess HRQoL. Differences between patients
with and without asthma were identified using chi-square tests for categorical
variables and t-tests for continuous variables. Multiple regression was used to
assess the association of asthma with HRQoL while accounting for potential con-
founds, including age, gender, number of co-morbid conditions, possession of pri-
vate insurance, alcohol use, exercise behavior, and cigarette smoking. RESULTS:
Seventy-six percent (n9108) of respondents were familiar with asthma. Physician
diagnosis of asthma was reported by 4% of the sample (n415), and the remaining
96% (n11,585) served as the control group. Asthma patients were younger (36 vs.
41, p0.001), more likely to be female (61% vs. 50%, p.001), have private insurance
(60% vs. 53% p0.01), drink alcohol (68% vs. 60%, p.01), and had more co-morbid
conditions (0.73 vs. 0.32 p0.001). Relative to controls, asthma patients had lower
MCS (42.41 vs. 46.99, p0.001), PCS (47.27 vs. 50.58, p0.001) and SF-6D health
utilities (0.66 vs. 0.73, p0.001). Asthma was associated with significantly lower
HRQoL after adjusting for age, gender, drinking, smoking, exercise, insurance, and
comorbidities, with MCS lower by 2.59 points (p0.001), PCS lower by 3.15 points
(p0.001), and SF-6D lower by 0.05 points (p0.001). CONCLUSIONS: Asthma is
associated with significant HRQoL burden, even after adjusting for covariates. This
analysis may underestimate the burden of asthma, as undiagnosed asthma pa-
tients were likely included in the control group.
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OBJECTIVES: The COPD Assessment Test (CAT) is a short, validated questionnaire
designed to measure the impact that Chronic Obstructive Pulmonary Disease
(COPD) has on the wellbeing and daily life of people living with COPD. The eight
items pertain to COPD symptoms and impact on life, and are rated using a six-point
scale, ranging from zero to five. From its original paper validation, the CAT has
migrated through tomany electronic platforms such as theweb, tablet devices, and
hand-held devices. Usability testing studies have been conducted to test the mi-
gration of the CAT to these platforms. The results have proved that the migration
does not alter the way in which the items are interpreted and how the questions
are completed by peoplewith COPD.More recently, the CAThas been developed for
use as a smart phone app to increase accessibility for people with COPD.
METHODS: A qualitative study was conducted to test the usability of the app with
ten people diagnosed with COPD. Participants completed the CAT using a smart
phone, and were then asked questions that probed on the usability of the ques-
tionnaire as a smart phone app. RESULTS: Due to the CAT being short and concise,
the smart phone app works very well for hosting such a questionnaire. Navigating
around the screen and selecting responses to the questions were completed with
nomajor concerns for half of the patients. Others commented that the app version
could benefit from the functionality of manually increasing the screen size, as this
was not implemented before the usability testingwas conducted, and is a common
feature of smart phones. CONCLUSIONS: Although some further work is still re-
quired before the app is finalised, this study showed that the CAT has great poten-
tial for becoming accessible in many different electronic platforms.
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OBJECTIVES: This study aimed to explore the impact of smoking on quality of life
and productivity in Chronic Obstructive Pulmonary Disease (COPD). METHODS:
Data from the National Health and Wellness Survey (NHWS) were used for this
study. Respondents aged 40 reporting diagnosiswith COPD, chronic bronchitis, or
emphysema in the United States in 2009 and 2010 were included, using 2010 data
for individuals completing the survey in both years. The smoking group included
subjects diagnosed with COPD and who reported currently smoking (n1685). The
former smoker group consisted of those diagnosed with COPD who reported not
smoking in the last 11 years (n1932). Health-related quality of life (HRQoL) was
assessed with the physical (PCS) and mental component summary (MCS) scores
from the SF-12v2, and the SF-6D. The Work Productivity and Activity Impairment
scale (WPAI) assessed productivity, including absenteeism, presenteeism, and
overall work and non-work activity impairment. Multivariate generalized linear
models predicted HRQoL variables using maximum likelihood estimation and an
identity function. This approachwas also used to predict productivity impairment,
with a negative binomial distribution and a log-link function. Covariates included
age, sex, race, insurance status, marital status, income, BMI, alcohol use, exercise,
and asthma diagnosis. RESULTS: The multivariable results showed the following
HRQoL differences between current smokers and former smokers with COPD: MCS
(44.8 vs. 46.7, p0.001), PCS (35.1 vs. 35.8, p0.079), SF-6D (0.63 vs. 0.65, p0.001).
Model results for productivity data estimated the following differences: absentee-
ism (3% vs. 1%, p0.355) presenteeism (23% vs. 18%, p0.010), overall work impair-
ment (25% vs. 21%, p0.043) and activity impairment (52% vs. 49%, p0.004).
CONCLUSIONS: Compared with former smokers quitting 10 years prior, COPD
sufferers currently smoking have poorer MCS scores, equivalent PCS and health
utility scores. They also show similar absenteeism, greater presenteeism and
mildly impaired overall work and activity impairment.
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OBJECTIVES: To establish the profile of the demand for interventions to quit smok-
ing among smokers inMexico, estimate themaximumwillingness to pay (WTP) for
an effective smoking cessation treatment and to identify smokers’ background,
environmental, demographic, and socioeconomic factors associated with this
valuation.METHODS: From the Global Adult Tobacco Survey in Mexico 2009, there
was selected the sample of analysis constituted by 1626 current smokers. A cross-
sectional study was performed. A statistical association and descriptive analysis
were conducted to describe smokers and their WTP using tobacco-related back-
ground information, environmental, socioeconomic and demographic variables.
RESULTS: 82.2 % of the current smokers who did not want to quit were men,
whereas between those who wanted to quit, 74.9 % were men. In the latter group,
49.8 % of smokers had been consuming tobacco with a daily frequency, for more
than 16 years, 57 % hadmade cessation attempts in the past, and around 10% knew
about the existence of centers to help quit smoking. The WTP for an effective
cessationmethodwas on average $2708Mexican pesos. An increase was identified
in the WTP as the educational level is increased using as reference to the smokers
without formal education. The individuals of the quintiles of socioeconomic status
(SES) 4 and 5 have a major WTP that the individuals of the quintile 1.
CONCLUSIONS: The evidence showed in the present study, will inform and sup-
port policymakers in the design and implementation of smoking cessation inter-
ventions. The study documents the need that these interventions incorporate
components in correspondence with the smokers’ profiles identified to improve
the effectiveness of the interventions to quit smoking, among Mexican smokers.
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OBJECTIVES: Asthma prevalence, morbidity and mortality have continued to in-
crease in the United States over the last decades. Disease management programs
for asthma have become a priority for managed care organizations (MCOs) in order
to optimize the process of care, manage utilization, and improve outcomes. The
objective of this study was to investigate how MCOs currently approach asthma
treatment and management and to identify their biggest challenges and opportu-
nities in improving asthma outcomes, and to determine if publication of revised
asthma guidelines by the National Heart, Lung and Blood Institute (NHLBI) in 2007
changed MCOs’ approach to asthma management. METHODS: A web and paper-
based survey tool was updated from a previous survey whose results were pub-
lished in 2005, and administered to a national sample of 383MCOmedical directors
Descriptive statistics were calculated for all variables. RESULTS: All 61 (15.9%)
responding medical directors collectively serve all regions of the United States,
with almost half servingMedicare and/or Medicaid patients. All directors surveyed
reported that their organizations monitor asthma patients. Plans use a variety of
asthmamanagement activities, including self-management education (80%), edu-
cational materials by mail (70%), general member education (65%) and behavior
modification programs (60%). Most commonly cited factors impeding the provision
of effective asthma carewere noncompliancewith asthma treatment, the inappro-
priate use ofmedications, and the need formultiplemedications. Descriptive com-
parisons show that results are very similar to those from the 2005 survey.
CONCLUSIONS: Survey results show that health plans rely on an array of strategies
to manage asthma patients. Education appears to be an essential part of most
plans’ approaches to disease and cost management. Comparing our results to
those reported in the 2005 study, the 2007 NHLBI guidelines appear to not have
greatly impacted the approach MCO’s take towards asthma management.
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OBJECTIVES: Palavizumab (Synagis) is used in the prevention of seasonal respira-
tory syncytial virus (RSV) infections. The purpose of this study was to assess the
impact of palavizumab use on pneumonia, bronchiolitis and all-cause costs among
children.METHODS:Mississippi Medicaid data for RSV seasons October 1 - March
31 of 2009-2010 and 2010-2011 were used. For each season, pre-term children age 2
years or less at the end of the season were classified as receiving palavizumab or
not. Users and non-users were matched (1:1) on age, gender, race and presence of
chronic lung disease with non-users assigned the index date for the corresponding
palavizumab user. Outcomes included diagnoses of pneumonia or bronchiolitis
within 30 days after the index date and all-cause costs. Costs were compared using
paired t-tests. Conditional logistic regression was used to assess the impact of
palavizumab on prevention of pneumonia and bronchiolitis when controlling for
pre-term stage. RESULTS: In the 2009-2010 season, 337 palavizumab users and 337
non-users were identified. palavizumab users had lower likelihood of diagnoses of
pneumonia (OR: 0.480; 95%CI: 0.213-1.081; p0.08) and bronchiolitis (OR: 0.596; 95%
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